CytoDyn (CYDY) Share-based Compensation (2010 - 2026)
CytoDyn's (CYDY) quarterly Share-based Compensation came in at $444000.0 in Q1 2026, up 1010.0% YoY from $40000.0 in Q1 2025, and down 68.29% on a QoQ basis from $1.4 million in Q4 2025.
CytoDyn (CYDY) Share-based Compensation (2010 - 2026) Analysis & Trends
CytoDyn (CYDY) has 17 years of Share-based Compensation data on file, last reported at $444000.0 in Q1 2026.
- Quarterly Share-based Compensation rose 1010.0% year-over-year to $444000.0 in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $1.3 million (up 6.59% YoY) and the FY2025 annual result came in at $1.7 million, down 29.61% from the prior year.
- Share-based Compensation fell to $444000.0 in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.0 million in Q2 2022 to a low of -$400000.0 in Q1 2022.
- A 5-year average of $478470.6 and a median of $345000.0 in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 121.05% — and 2026, when it jumped 1010.0%.
- Tracing CYDY's Share-based Compensation over 5 years: stood at $310000.0 in 2022, then tumbled by 68.39% to $98000.0 in 2023, then surged by 447.96% to $537000.0 in 2024, then jumped by 160.71% to $1.4 million in 2025, then plunged by 68.29% to $444000.0 in 2026.
- The last three Share-based Compensation figures came in at $444000.0 (Q1 2026), $1.4 million (Q4 2025), and $179000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - | 444,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 444,000.00 |
| Feb 28, 2026 | 444,000.00 |
| Nov 30, 2025 | 1.40 Mn |
| Nov 30, 2025 | 1.40 Mn |
| Aug 31, 2025 | 179,000.00 |
| Aug 31, 2025 | 179,000.00 |
| May 31, 2025 | 599,000.00 |
| May 31, 2025 | 599,000.00 |
| Feb 28, 2025 | 40,000.00 |
| Feb 28, 2025 | 40,000.00 |
| Nov 30, 2024 | 537,000.00 |
| Nov 30, 2024 | 537,000.00 |
| Aug 31, 2024 | 136,000.00 |
| Aug 31, 2024 | 136,000.00 |
| May 31, 2024 | 471,000.00 |
| May 31, 2024 | 471,000.00 |
| Feb 29, 2024 | 900,000.00 |
| Feb 29, 2024 | 900,000.00 |
| Nov 30, 2023 | 98,000.00 |
| Nov 30, 2023 | 98,000.00 |